1 NOTICE REQUIREMENTS FOR PRESCRIPTION MONITORING PROGRAMS This project was supported by Grant No. G1299ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government.
2 Clicking on one of the options below will take you directly to that page. Introduction Colorado Kansas Maryland Minnesota Oregon Rhode Island Utah Vermont Virginia
3 Introduction This memorandum compiles all of the statutes and regulations from states that require health care providers and/or dispensers to provide notice to their patients or clients that their information will be shared with the state prescription monitoring program and/or that their information contained within the prescription monitoring program database may be accessed. Back to top
4 Colorado ADC 719-1: West's Colorado Revised Statutes Annotated (2013) Title 12. Professions and Occupations Health Care Article Pharmacists, Pharmacy Businesses, and Pharmaceuticals Part 4. Electronic Monitoring of Prescription Drugs Prescription drug use monitoring program (1) The board shall develop or procure a prescription controlled substance electronic program to track information regarding prescriptions for controlled substances dispensed in Colorado, including the following information: (a) The date the prescription was dispensed; (b) The name of the patient and the practitioner; (c) The name and amount of the controlled substance; (d) The method of payment; (e) The name of the dispensing pharmacy; and (f) Any other data elements necessary to determine whether a patient is visiting multiple practitioners or pharmacies, or both, to receive the same or similar medication. (2) Each practitioner and each dispensing pharmacy shall disclose to a patient receiving a controlled substance that his or her identifying prescription information will be entered into the program database and may be accessed for limited purposes by specified individuals. (3) The board shall establish a method and format for prescription drug outlets to convey the necessary information to the board or its designee. The method must not require more than a one-time entry of data per patient per prescription by a prescription drug outlet. (4) The division may contract with any individual or public or private agency or organization in carrying out the data collection and processing duties required by this part 4.
5 West's Colorado Administrative Code (2013) Title 700. Department of Regulatory Agencies 719. State Board of Pharmacy 3 CCR Pharmacy Rules and Regulations 719-1: ELECTRONIC PRESCRIPTION MONITORING PROGRAM PATIENT NOTIFICATION Prescription Drug Outlets shall disclose to patients receiving controlled substance prescriptions that their prescription information is being submitted to the PDMP, and that this prescription information may be queried by specific individuals for a limited number of purposes as authorized by statute.... Back to Top
6 Kansas ADC Kansas Administrative Regulations (2013) Agency 68. Board of Pharmacy Article 21. Prescription Monitoring Program Notice of requests for information. Each dispenser who may access information maintained by the board on each drug of concern and schedule II through IV drug dispensed to one of the dispenser's patients for the purpose of providing medical or pharmaceutical care shall notify the patient of this access to prescription monitoring information by performing either of the following: (a) Posting an easily viewable sign at the place where prescription orders are issued or accepted for dispensing; or (b) providing written material about the dispenser's access to prescription monitoring information. Back to Top
7 Maryland ADC Code of Maryland Regulations (2013) Title 10 Department of Health and Mental Hygiene Subtitle 47 Alcohol and Drug Abuse Administration Chapter 07 Prescription Drug Monitoring Program.05 Notice to Patients. A. Dispenser. (1) Any dispenser who intends to request prescription monitoring data from the Program may post a sign that can be easily viewed by the public at the place where the prescription is delivered to the dispenser. (2) The sign shall disclose to the public that the dispenser may access prescription monitoring data on a patient for whom a prescription for a monitored prescription drug is presented. (3) In lieu of posting a sign, the dispenser may provide such notice in written material provided to the patient. B. Prescriber. (1) Any prescriber who intends to request prescription monitoring data from the Program may post a sign that can be easily viewed by the public that discloses to the public that the prescriber may access prescription monitoring data on a patient. (2) In lieu of posting a sign, the prescriber may provide such notice in written material provided to the patient. Back to Top
8 Minnesota A.192 Minnesota Statutes Annotated (2013) Health (Ch ) Chapter 152. Drugs; Controlled Substances Prescriptions Controlled substances prescription electronic reporting system... Subd. 4. Reporting requirements; notice. (a) Each dispenser must submit the following data to the board or its designated vendor, subject to the notice required under paragraph (d): (1) name of the prescriber; (2) national provider identifier of the prescriber; (3) name of the dispenser; (4) national provider identifier of the dispenser; (5) prescription number; (6) name of the patient for whom the prescription was written; (7) address of the patient for whom the prescription was written; (8) date of birth of the patient for whom the prescription was written; (9) date the prescription was written; (10) date the prescription was filled; (11) name and strength of the controlled substance; (12) quantity of controlled substance prescribed; (13) quantity of controlled substance dispensed; and (14) number of days supply.
9 (b) The dispenser must submit the required information by a procedure and in a format established by the board. The board may allow dispensers to omit data listed in this subdivision or may require the submission of data not listed in this subdivision provided the omission or submission is necessary for the purpose of complying with the electronic reporting or data transmission standards of the American Society for Automation in Pharmacy, the National Council on Prescription Drug Programs, or other relevant national standard-setting body. (c) A dispenser is not required to submit this data for those controlled substance prescriptions dispensed for: (1) individuals residing in licensed skilled nursing or intermediate care facilities; (2) individuals receiving assisted living services under chapter 144G or through a medical assistance home and community-based waiver; (3) individuals receiving medication intravenously; (4) individuals receiving hospice and other palliative or end-of-life care; and (5) individuals receiving services from a home care provider regulated under chapter 144A. (d) A dispenser must not submit data under this subdivision unless a conspicuous notice of the reporting requirements of this section is given to the patient for whom the prescription was written.... Minnesota Statutes Annotated (2013) Public Welfare and Related Activities (Ch ) Chapter 245A. Human Services Licensing 245A.192. Providers licensed to provide treatment of opioid addiction.... Subd. 11. Prescription monitoring program. (a) Upon admission to a methadone clinic outpatient treatment program, clients shall be notified that the Department of Human Services and the medical director will monitor the prescription monitoring program to review the prescribed controlled drugs the clients have received. The medical director or the medical director s delegate must review data from the Minnesota Board of Pharmacy, prescription monitoring program (PMP) established under section prior to the client being ordered any controlled substance as defined under section , subdivision 1, paragraph (b), including medications used for the treatment of opioid addiction. The subsequent reviews of the PMP data must occur quarterly and be documented in the client s individual file.
10 When the PMP data shows a recent history of multiple prescribers or multiple prescriptions for controlled substances, then subsequent reviews of the PMP data must occur monthly and be documented in the client s individual file. If, at any time, the medical director believes the use of the controlled substances places the client at risk of harm, the program must seek consent to discuss the client s opioid treatment with other prescribers and must seek consent for the other prescriber to disclose to the opioid treatment programs medical director the client s condition that formed the basis of the other prescriptions. Additionally, any findings from the PMP data that are relevant to the medical director s course of treatment for the client must be documented in the client s individual file. A review of the PMP is not required for every medication dose adjustment.... Back to Top
11 Oregon (eff. until Jan. 1, 2014) (eff. Jan. 1, 2014) ADC West's Oregon Revised Statutes Annotated (2013) Title 36. Public Health and Safety Chapter 431. State and Local Administration and Enforcement of Health Laws Prescription Monitoring Program (Program) Prescription monitoring program <Text of section effective until January 1, 2014> (1)(a) The Oregon Health Authority, in consultation with the Prescription Monitoring Program Advisory Commission, shall establish and maintain a prescription monitoring program for monitoring and reporting prescription drugs dispensed by pharmacies in Oregon that are classified in schedules II through IV under the federal Controlled Substances Act, 21 U.S.C. 811 and 812, as modified under ORS (b)(a) To fulfill the requirements of this subsection, the authority shall establish, maintain and operate an electronic system to monitor and report drugs described in paragraph (a) of this subsection that are dispensed by prescription. (B) The system must operate and be accessible by practitioners and pharmacies 24 hours a day, seven days a week. (C) The authority may contract with a state agency or private entity to ensure the effective operation of the electronic system. (2) In consultation with the commission, the authority shall adopt rules for the operation of the electronic prescription monitoring program established under subsection (1) of this section, including but not limited to standards for: (a) Reporting data; (b) Providing maintenance, security and disclosure of data; (c) Ensuring accuracy and completeness of data; (d) Complying with the federal Health Insurance Portability and Accountability Act of 1996 (P.L ) and regulations adopted under it, including 45 C.F.R. parts 160 and 164, federal
12 alcohol and drug treatment confidentiality laws and regulations adopted under those laws, including 42 C.F.R. part 2, and state health and mental health confidentiality laws, including ORS , and to ; (e) Ensuring accurate identification of persons or entities requesting information from the database; (f) Accepting printed or nonelectronic reports from pharmacies that do not have the capability to provide electronic reports; and (g) Notifying a patient, before or when a drug classified in schedules II through IV is dispensed to the patient, about the prescription monitoring program and the entry of the prescription in the system. (3) The authority shall submit an annual report to the commission regarding the prescription monitoring program established under this section. West's Oregon Revised Statutes Annotated (2013) Title 36. Public Health and Safety Chapter 431. State and Local Administration and Enforcement of Health Laws Prescription Monitoring Program (Program) Prescription monitoring program <Text of section effective January 1, 2014> (1)(a) The Oregon Health Authority, in consultation with the Prescription Monitoring Program Advisory Commission, shall establish and maintain a prescription monitoring program for monitoring and reporting prescription drugs dispensed by pharmacies in Oregon that are classified in schedules II through IV under the federal Controlled Substances Act, 21 U.S.C. 811 and 812, as modified by the State Board of Pharmacy by rule under ORS (b)(a) To fulfill the requirements of this subsection, the authority shall establish, maintain and operate an electronic system to monitor and report drugs described in paragraph (a) of this subsection that are dispensed by prescription. (B) The system must operate and be accessible by practitioners and pharmacies 24 hours a day, seven days a week. (C) The authority may contract with a state agency or private entity to ensure the effective operation of the electronic system.
13 (2) In consultation with the commission, the authority shall adopt rules for the operation of the electronic prescription monitoring program established under subsection (1) of this section, including but not limited to standards for: (a) Reporting data; (b) Providing maintenance, security and disclosure of data; (c) Ensuring accuracy and completeness of data; (d) Complying with the federal Health Insurance Portability and Accountability Act of 1996 (P.L ) and regulations adopted under it, including 45 C.F.R. parts 160 and 164, federal alcohol and drug treatment confidentiality laws and regulations adopted under those laws, including 42 C.F.R. part 2, and state health and mental health confidentiality laws, including ORS , and to ; (e) Ensuring accurate identification of persons or entities requesting information from the database; (f) Accepting printed or nonelectronic reports from pharmacies that do not have the capability to provide electronic reports; and (g) Notifying a patient, before or when a drug classified in schedules II through IV is dispensed to the patient, about the prescription monitoring program and the entry of the prescription in the system. (3) The authority shall submit an annual report to the commission regarding the prescription monitoring program established under this section. Oregon Administrative Rules Compilation (2013) Chapter 410. Oregon Health Authority, Division of Medical Assistance Programs Division 121. Pharmaceutical Services Non-medicaid Rules Prescription Drug Monitoring Program Notification to Patients Using language provided by the Authority, a pharmacy shall notify each patient receiving a controlled substance about the Prescription Drug Monitoring Program before or when the controlled substance is dispensed to the patient. The notification shall include that the prescription will be entered into the system. Back to Top
14 Rhode Island West's General Laws of Rhode Island Annotated (2013) Title 21. Food and Drugs Chapter 28. Uniform Controlled Substances Act Article III. Regulation of Manufacturing, Distributing, Prescribing, Administering, and Dispensing Controlled Substances Electronic prescription database. (a) The information contained in any prescription drug monitoring database maintained by the department of health pursuant to section 3.18 of this chapter shall be disclosed only: (1) To a practitioner who certifies that the requested information is for the purpose of evaluating the need for or providing medical treatment for a current patient to whom the practitioner is prescribing or considering prescribing a controlled substance; (2) To a pharmacist who certifies that the requested information is for a current client to whom the pharmacist is dispensing or considering dispensing a controlled substance; (3) Pursuant to a valid search warrant based on probable cause to believe a violation of federal or state criminal law has occurred and that specified information contained in the database would assist in the investigation of the crime; (4) To a patient who requests his or her own prescription information, or the parent or legal guardian of a minor child who requests the minor child s prescription information; (5) To a health professional regulatory board that documents, in writing, that the requested information is necessary for an investigation related to licensure, renewal or disciplinary action involving the applicant, licensee or registrant to whom the requested information pertains; (6) To any vendor or contractor with whom the department has contracted to establish or maintain the electronic system of the prescription drug monitoring database; or (7) To public or private entities for statistical, research or educational purposes, after removing the patient and prescriber information that could be used to identify individual patients. This shall not include entities receiving a waiver from the institutional review board; (b) Information stored in the prescription drug monitoring database shall include only the following:
15 (1) Patient s first and last name, and/or patient identification number; provided, however, the patient s social security number shall not be recorded in whole or in part, patient sex, patient date of birth, and patient address; (2) Prescribing practitioner s name and drug enforcement administration prescriber information number; (3) Prescribing practitioner s office or hospital contact information; (4) Prescription name, prescription number, prescription species code, national drug code number, prescription dosage, prescription quantity, days supply, new-refill code, number of refills authorized, date the prescription was written, date the prescription was filled, payment type; provided, however, no credit card number shall be recorded in whole or in part; and (5) The drug enforcement administration pharmacy number of the pharmacy filling the prescription. (c) The department shall disclose any information relating to a patient maintained in the prescription drug monitoring database to that patient, at no cost to the patient, within thirty (30) business days after the department receives a written request from the patient for the information. This information shall include the records maintained by the department pursuant to subsection (e). Notwithstanding the above, the department may, at the request of the law enforcement agency, withhold for up to sixty (60) days following the conclusion of a law enforcement investigation, the disclosure to the patient that information has been obtained pursuant to subdivision (a)(3). (d) A patient may request from the dispensing pharmacy correction of any inaccurate information contained within the prescription drug monitoring database in accordance with the procedure specified by subsection (c). (e) The department shall, for the period of time that prescription information is maintained, maintain records of the information disclosed through the prescription drug monitoring database, including, but not limited to: (1) The identity of each person who requests or receives information from the prescription drug monitoring database and the organization, if any, the person represents; (2) The information released to each person or organization and the basis for its release under subsection (a); and (3) The dates the information was requested and provided. (f) Prescription information contained within the prescription drug monitoring database shall be removed no later than five (5) years from the date the information is entered into the database.
16 Records in existence prior to the enactment of this section shall be removed no later than ten (10) years from the date the information is entered into the database. (g) The department shall promptly notify any affected individual of an improper disclosure of information from the prescription drug monitoring database or a breach in the security of the prescription drug monitoring database that poses a significant risk of disclosure of patient information to an unauthorized individual. (h) At the time of signing a prescription which is required by the department to be entered into the prescription drug monitoring database, the prescribing practitioner shall inform the patient in writing of the existence of the prescription drug monitoring database, the patient s right to access their own prescription information, and the name and contact information of the agency operating the program. (i) No person shall access information in the prescription monitoring database except to the extent and for the purposes authorized by subsection (a). (j) In any civil action allowing a violation of this chapter, the court may award damages, including punitive damages, and reasonable attorneys fees and costs to a prevailing plaintiff, and injunctive and any other appropriate relief. (k) Any pharmacist who, in his or her professional judgment, refuses to fill a prescription based on information contained within the prescription drug monitoring database shall inform the prescribing physician within twenty-four (24) hours. Back to Top
17 Utah West's Utah Code Annotated (2013) Title 26. Utah Health Code Chapter 1. Department of Health Organization Duty to establish program to reduce deaths and other harm from prescription opiates used for chronic noncancer pain (1) As used in this section, opiate means any drug or other substance having an addictionforming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. (2) In addition to the duties listed in Section , the department shall develop and implement a two-year program in coordination with the Division of Professional Licensing, the Utah Labor Commission, and the Utah attorney general, to: (a) investigate the causes of and risk factors for death and nonfatal complications of prescription opiate use and misuse in Utah for chronic pain by utilizing the Utah Controlled Substance Database created in Section 58-37f-201; (b) study the risks, warning signs, and solutions to the risks associated with prescription opiate medications for chronic pain, including risks and prevention of misuse and diversion of those medications; (c) provide education to health care providers, patients, insurers, and the general public on the appropriate management of chronic pain, including the effective use of medical treatment and quality care guidelines that are scientifically based and peer reviewed; and (d) educate the public regarding: (i) the purpose of the Controlled Substance Database established in Section 58-37f-201; and (ii) the requirement that a person's name and prescription information be recorded on the database when the person fills a prescription for a schedule II, III, IV, or V controlled substance. Back to Top
18 Vermont ADC :1 West's Vermont Statutes Annotated (2013) Title Eighteen. Health Part 5. Foods and Drugs Chapter 84A. Vermont Prescription Monitoring System Creation; implementation (a) The Department shall maintain an electronic database and reporting system for monitoring Schedules II, III, and IV controlled substances, as defined in 21 C.F.R. Part 1308, as amended and as may be amended, that are dispensed within the State of Vermont by a health care provider or dispenser or dispensed to an address within the State by a pharmacy licensed by the Vermont Board of Pharmacy. (b) As required by the department, every dispenser who is licensed by the Vermont board of pharmacy shall report to the department in a timely manner data for each controlled substance in Schedules II, III, and IV, as amended and as may be amended, dispensed to a patient within Vermont. Reporting shall not be required for: (1) a drug administered directly to a patient; or (2) a drug dispensed by a health care provider at a facility licensed by the department, provided that the quantity dispensed is limited to an amount adequate to treat the patient for a maximum of 48 hours. (c) Data for each controlled substance that is dispensed shall include the following: (1) patient identifier, which may include the patient's name and date of birth; (2) drug dispensed; (3) date of dispensing; (4) quantity and dosage dispensed; (5) the number of days' supply; (6) health care provider; and (7) dispenser.
19 (d) The data shall be provided in the electronic format defined by the department. To the extent possible, the format shall not require data entry in excess of that required in the regular course of business. Electronic transmission is not required if a waiver has been granted by the department to an individual dispenser. The department shall strive to create VPMS in a manner that will enable real-time transmittal to VPMS and real-time retrieval of information stored in VPMS. (e) It is not the intention of the Department that a health care provider or a dispenser shall have to pay a fee or tax or purchase hardware or proprietary software required by the Department specifically for the establishment, maintenance, or transmission of the data. The Department shall seek grant funds and take any other action within its financial capability to minimize any cost impact to health care providers and dispensers. (f) The department shall purge from VPMS all data that is more than six years old. (g) The commissioner shall develop and provide advisory notices, which shall make clear that all prescriptions for controlled drugs in Schedules II, III, and IV are entered into a statewide database in order to protect the public. The notices shall be distributed at no cost to dispensers and health care providers who are subject to this chapter. (h) A dispenser shall be subject to discipline by the board of pharmacy or by the applicable licensing entity if the dispenser intentionally fails to comply with the requirements of subsection (b), (c), or (d) of this section. Vermont Administrative Code (2013) Title 12. Agency of Human Services Subtitle 5. Department of Health General Rule 21. Prescription Monitoring System :1. GENERAL PROVISIONS Section 1.1 Purpose. This rule implements the Vermont Prescription Monitoring System ( VPMS ) created by 18 V.S.A. Chapter 84A, which authorizes the Department to establish an electronic database and reporting system for electronic monitoring of prescriptions of certain controlled substances to promote the public health through enhanced opportunities for treatment for and prevention of abuse of controlled substances, without interfering with the legal medical use of those substances. Section 1.2 Authority. This rule is adopted under the authority of 3 V.S.A. 801(b)(11) and 3003(a) and 18 V.S.A. 102 and 4287.
20 Section 1.3 Effective Date. This rule shall be effective on June 1, Section 1.4 Definitions. The definitions of terms contained in these rules are the same as those contained in 18 V.S.A If any of such legislative definitions are amended, the amended definitions shall be the definitions of the terms contained in these rules. Additional definitions for purposes of these rules: 1. Commissioner means the Commissioner of the Vermont Department of Health. 2. Controlled substance means a substance listed on Schedules II, III or IV as defined in 21 C.F.R. Part 1308, as amended and as may be amended. 3. Report of Controlled Substances Dispensed means the report generated by dispensers of required data on each reportable prescription dispensed pursuant to this rule. 4. Department means the Vermont Department of Health. 5. Dispense or dispensing shall have the same meaning as those terms are defined in 26 V.S.A. 2022(5). 6. Pharmacist-manager shall have the same meaning as defined in the Vermont Board of Pharmacy Administrative Rules. 7. Reportable prescription means each controlled substance dispensed from any pharmacy to a patient within Vermont during the reporting period, except (1) a controlled substance administered directly to a patient; or (2) a controlled substance dispensed by a health care provider at a facility licensed by the Department of Health, provided that the quantity dispensed is limited to an amount adequate to treat the patient for a maximum of 48 hours. 8. VPMS report means a report released by the Department of information from the VPMS database to an individual or entity eligible to receive the information pursuant to a specific provision of law. Section 1.5 Distribution of Advisory Notices. Each dispenser shall provide to customers to whom a reportable prescription is dispensed the advisory notice developed and distributed by the Department by: 1) prominently displaying the advisory notice in a manner readily accessible to its customers, or 2) duplicating the complete text of the advisory notice in another format, such as by printing
21 on customer receipts or on patient instructions or providing a written insert for delivery to the patient, or 3) both. Section 1.6 Confidentiality. All data submitted to the VPMS database pursuant to this rule are confidential, not subject to disclosure pursuant to public records law, and shall only be disclosed as provided in 18 V.S.A or this rule. A person who receives information from the VPMS database shall only use that information as permitted by law and shall share that information only with other persons eligible by law to receive it. There is no restriction on the right of a patient to share his or her own data received from the VPMS database. Section 1.7 Correction of Information in the VPMS Database. A patient, health care provider, dispenser, or professional licensure board, or other individual having knowledge of what they believe to be an error in the VPMS database, may submit a request to correct information in writing to the Department that shall include: 1. A statement explaining in detail the basis for the requested correction; 2. The precise change requested; 3. Documentation of the error and of the correct information; 4. The requester's name, address, telephone number and original signature. The Department will review all requests to correct information in the VPMS database and contact the reporting pharmacy that provided the data. If the reporting pharmacy concurs that the data should be corrected as requested, the Department will correct the data. If the reporting pharmacy does not concur, the Department will decline to make the change and refer the requester to the reporting pharmacy. Upon request by a health care provider, dispenser or professional licensure board or other individual, and as permitted by 18 V.S.A and Part III of this rule, the Department will notify the requester whether the requested correction has been made. Any patient who has requested a correction will be notified of whether the requested correction has been made. Back to Top
22 Virginia 18 VAC Virginia Administrative Code (2013) Title 18. Professional and Occupational Licensing Vac Agency No. 76. Department of Health Professions Chapter 20. Regulations Governing the Prescription Monitoring Program 18 VAC Notice of requests for information. A. Any dispenser who intends to request information from the program for a recipient or prospective recipient of a Schedule II, III, or IV controlled substance shall post a sign that can be easily viewed by the public at the place where the prescription is accepted for dispensing and that discloses to the public that the pharmacist may access information contained in the program files on all Schedule II, III or IV prescriptions dispensed to a patient. In lieu of posting a sign, the dispenser may provide such notice in written material provided to the recipient, or may obtain written consent from the recipient. B. Any prescriber who intends to request information from the program about a patient or prospective patient shall post a sign that can be easily viewed by the public that discloses to the public that the prescriber may access information contained in the program files on all Schedule II, III or IV prescriptions dispensed to a patient. In lieu of posting a sign, the prescriber may provide such notice in written material provided to the patient, or may obtain written consent from the patient. Back to Top
0 Page of S. Introduced by Senator Sears Referred to Committee on Date: Subject: Health; prescription drugs; Vermont Prescription Monitoring System Statement of purpose of bill as introduced: This bill
LC 0 Regular Session // (SCT/ps) D R A F T SUMMARY Requires Oregon Health Authority to disclose prescription monitoring information to practitioner or pharmacist or member of practitioner s or pharmacist
PLEASE READ The official text of New Jersey Statutes can be found through the home page of the New Jersey Legislature http://www.njleg.state.nj.us/ New Jersey Statutes Annotated (N.J.S.A.), published by
State, District, or Territory Alabama Arizona Arkansas Colorado Connecticut Delaware Georgia Guam Criteria for Mandatory Enrollment or Query of PDMP Before renewing an Alabama Controlled Substances Certificate,
PRESCRIPTION MONITORING PROGRAM STATE PROFILES LOUISIANA Research current through July 2014. This project was supported by Grant No. G1399ONDCP03A, awarded by the Office of National Drug Control Policy.
Oregon Prescription Drug Monitoring Program Terms & Conditions of Account Use Agreement Statutory Authority: The Oregon Health Authority (OHA) was given authority under ORS 431.962 to establish and maintain
2015 ANNUAL REVIEW OF PRESCRIPTION MONITORING PROGRAMS Research current through September 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy.
VERMONT2007 Vermont Prescription Monitoring Program Report to the Legislature on Act 205 January 15, 2008 108 Cherry Street, PO Box 70 Burlington, VT 05402 1.802.863.7341 healthvermont.gov Vermont Prescription
AITKIN COUNTY GUIDELINES AND PROCEDURES FOR MINNESOTA GOVERNMENT DATA PRACTICES ACT Aitkin County Adopted by the Aitkin County Board of Commissioners July 28, 2015 To the extent that the Minnesota Government
CHAPTER 10 AN ACT concerning overdose prevention and sterile syringe access programs, and amending P.L.2006, c.99 and P.L.2013, c.46. BE IT ENACTED by the Senate and General Assembly of the State of New
SECTION.1800 - PRESCRIPTIONS 21 NCAC 46.1801 EXERCISE OF PROFESSIONAL JUDGMENT IN FILLING PRESCRIPTIONS (a) A pharmacist or device and medical equipment dispenser shall have a right to refuse to fill or
No. 75. An act relating to strengthening Vermont s response to opioid addiction and methamphetamine abuse. (H.522) It is hereby enacted by the General Assembly of the State of Vermont: Sec. 1. LEGISLATIVE
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015 ABC-MAP Board Meeting Agenda Prescription Drug Monitoring Background ABC-MAP Overview Board Responsibilities
MEMORANDUM TO: FROM: RE: Employees Human Resources AGENCY DRUG-FREE WORKPLACE POLICY Attached is a copy of the Mississippi Department of Health s established Drug-Free Workplace Policy. This policy reflects
ESSENTIAL ELEMENTS OF AN ELECTRONIC PRESCRIPTION MONITORING PROGRAM There currently is a wide variety of factors that characterize state electronic Prescription Monitoring Programs (PMPs), which originated
Rule 400 3 CCR 713-7 COLORADO MEDICAL BOARD RULES AND REGULATIONS FOR LICENSURE OF AND PRACTICE BY PHYSICIAN ASSISTANTS (PAs) INTRODUCTION BASIS. The authority for promulgation of Rule 400 ( these Rules
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE 201 KAR 9:260. Professional standards for prescribing and dispensing controlled substances.
The House Committee on Health and Human Services offers the following substitute to HB 972: A BILL TO BE ENTITLED AN ACT 1 2 3 4 5 6 7 8 9 10 11 12 13 To amend Chapter 34 of Title 43 of the Official Code
MTION OF STATE PREPTION NITONG PROGRAM PS This project was supported by Cooperative Agreement No. 202-DC-BX-K002 awarded by the Bureau of Justice Assistance. The Bureau of Justice Assistance is a component
SENATE.............. No. 2142 Tuesday, May 13, 2014 Text of the Senate Bill to increase opportunities for long-term substance abuse recovery (being the text of Senate, No. 2133, printed as amended). The
1 MINNESOTA STATUTES 2014 245C.02 CHAPTER 245C HUMAN SERVICES BACKGROUND STUDIES 245C.01 TITLE. 245C.02 DEFINITIONS. 245C.03 BACKGROUND STUDY; INDIVIDUALS TO BE STUDIED. 245C.04 WHEN BACKGROUND STUDY MUST
Article 29A. North Carolina Health Information Exchange Act. 90-413.1. Title. This act shall be known and may be cited as the "North Carolina Health Information Exchange Act." (2011-337, s. 1.) 90-413.2.
THE STATE EDUCATION DEPARTMENT / THE UNIVERSITY OF THE STATE OF NEW YORK / ALBANY, NY 12234 TO: FROM: SUBJECT: DATE: The Professional Practice Committee Douglas E. Lentivech Proposed Amendment to Section
HOUSE OF REPRESENTATIVES STAFF ANALYSIS BILL #: HB 1381 Prescription Drug Monitoring Program SPONSOR(S): Davis TIED BILLS: IDEN./SIM. BILLS: REFERENCE ACTION ANALYST STAFF DIRECTOR or BUDGET/POLICY CHIEF
RULES OF THE TENNESSEE BOARD OF NURSING R 1000-04 ADVANCED PRACTICE NURSES AND CERTIFICATES TABLE OF CONTENTS 1000-04-.01 Purpose and Scope 1000-04-.07 Processing of Applications 1000-04-.02 Definitions
Exceptions to the Rule: A Pharmacy Law Presentation Eric Roath, Pharm.D. Director of Professional Practice Michigan Pharmacists Association Objectives 1. Identify basic legal frameworks that govern the
CHAPTER 172 AN ACT concerning consumer credit reports and supplementing Title 56 of the Revised Statutes. BE IT ENACTED by the Senate and General Assembly of the State of New Jersey: C.56:11-28 Short title.
ISSUE DATE April 8, 2011 EFFECTIVE DATE April 8, 2011 MEDICAL ASSISTANCE BULLETIN NUMBER 03-11-01, 09-11-02, 14-11-01, 18-11-01 24-11-03, 27-11-02, 31-11-02, 33-11-02 SUBJECT Electronic Prescribing Internet-based
AN ACT relating to crime victims. CHAPTER 101 1 CHAPTER 101 (HB 500) Be it enacted by the General Assembly of the Commonwealth of Kentucky: Section 1. KRS 216B.400 is amended to read as follows: (1) Where
2012 Page 1 of 8 1 2 3 4 5 H.627 Introduced by Representative Pugh of South Burlington Referred to Committee on Date: Subject: Health; food and drugs; treatment of opiate addiction Statement of purpose:
NOTICES OF PROPOSED RULEMAKING Unless exempted by A.R.S. 41-1005, each agency shall begin the rulemaking process by first submitting to the Secretary of State s Office a Notice of Rulemaking Docket Opening
PLEASE NOTE: Legislative Information cannot perform research, provide legal advice, or interpret Maine law. For legal assistance, please contact a qualified attorney. Be it enacted by the People of the
Rule 400 3 CCR 713-7 COLORADO MEDICAL BOARD RULES AND REGULATIONS FOR LICENSURE OF AND PRACTICE BY PHYSICIAN ASSISTANTS BASIS. The authority for promulgation of Rule 400 ( these Rules ) by the Colorado
855-025-0001 DIVISION 25 CERTIFIED OREGON PHARMACY TECHNICIANS AND PHARMACY TECHNICIANS Purpose and Scope Transition from Registration of Technician to Licensure of Technician The purpose of the Pharmacy
RULES OF DEPARTMENT OF HEALTH DIVISION OF PAIN MANAGEMENT CLINICS CHAPTER 1200-34-01 PAIN MANAGEMENT CLINICS TABLE OF CONTENTS 1200-34-01-.01 Purpose 1200-34-01-.06 Notifications 1200-34-01-.02 Definitions
2012 Page 1 of 6 1 2 3 4 5 H.627 Introduced by Representative Pugh of South Burlington Referred to Committee on Date: Subject: Health; food and drugs; treatment of opiate addiction Statement of purpose:
SENATE/HOUSE FILE BY (PROPOSED BOARD OF NURSING BILL) A BILL FOR An Act relating to persons and activities regulated by the board of nursing. BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
Terms and Conditions Relating to Protected Health Information ( City PHI Terms ) Revised and Effective as of September 23, 2013 The City of Philadelphia is a Covered Entity as defined in the regulations
BUSINESS ASSOCIATE AGREEMENT THIS BUSINESS ASSOCIATE AGREEMENT (the AGREEMENT ) is entered into this (the "Effective Date"), between Delta Dental of Tennessee ( Covered Entity ) and ( Business Associate
HIPAA BUSINESS ASSOCIATE AGREEMENT This HIPAA Business Associate Agreement ("BA AGREEMENT") supplements and is made a part of any and all agreements entered into by and between The Regents of the University
THE FAIR CREDIT REPORTING ACT As a public service, the staff of the Federal Trade Commission (FTC) has prepared the following complete text of the Fair Credit Reporting Act (FCRA), 15 U.S.C. 1681 et seq.
BUSINESS ASSOCIATE AGREEMENT ( BAA ) Pursuant to the terms and conditions specified in Exhibit B of the Agreement (as defined in Section 1.1 below) between EMC (as defined in the Agreement) and Subcontractor
HIPAA Business Associate Agreement Sample Notice Disclaimer: Template Business Associate Agreement (45 C.F.R. 164.308) The information provided in this document does not constitute, and is no substitute
Allergy Treatment Center of New Jersey, P.C. 388 Pompton Avenue 415 Avenel Street Cedar Grove, NJ 07009 Avenel, NJ 07001 (973) 857 9890 (732) 636-7030 NOTICE OF PRIVACY PRACTICES Allergy Treatment Center
CHAPTER 63 PUBLIC HEALTH REGULATION MISCELLANEOUS CHANGES H.F. 467 AN ACT relating to programs and activities under the purview of the department of public health. Be It Enacted by the General Assembly
Chapter 93B. Occupational Licensing Boards. 93B-1. Definitions. As used in this Chapter: "License" means any license (other than a privilege license), certificate, or other evidence of qualification which
OHIO AUTOMATED RX REPORTING SYSTEM 2015 REPORT Steven W. Schierholt, Esq. Executive Director www.pharmacy.ohio.gov OHIO AUTOMATED RX REPORTING SYSTEM What is OARRS? To address the growing misuse and diversion
PUBLIC LAW 109 41 JULY 29, 2005 PATIENT SAFETY AND QUALITY IMPROVEMENT ACT OF 2005 VerDate 14-DEC-2004 11:17 Aug 05, 2005 Jkt 039139 PO 00041 Frm 00001 Fmt 6579 Sfmt 6579 E:\PUBLAW\PUBL041.109 APPS10 PsN:
S.B. NO. JAN 0 A BILL FOR AN ACT THE SENATE TWENTY-EIGHTH LEGISLATURE, 0 STATE OF HAWAII RELATED TO LICENSED MARRIAGE AND FAMILY THERAPISTS. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII: I 0
HEALTH OCCUPATIONS TITLE 19. SOCIAL WORKERS SUBTITLE 3. LICENSING 19-301. License required; exceptions; practice without license (a) In general. -- Except as otherwise provided in this title, an individual
FREQUENTLY ASKED QUESTIONS for the Revised: February 2014 NEW YORK STATE DEPARTMENT OF HEALTH Bureau of Narcotic Enforcement 1-866-811-7957 www.health.ny.gov/professionals/narcotic Online PMP Q: What is
THE FAIR CREDIT REPORTING ACT As a public service, the staff of the Federal Trade Commission (FTC) has prepared the following complete text of the Fair Credit Reporting Act (FCRA), 15 U.S.C. 1681 et seq.
PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Baumgartner, Chris - Director P O Box 47852 Olympia WA 98504-7852 Office: (360) 236-4806 Fax: (360) 236-2901 Email: Washington Washington
Prescription Drug Monitoring Program Center of Excellence at Brandeis Notes from the Field NF 4.1 Using PDMPs to Improve Medical Care: Washington State s Data Sharing Initiative with Medicaid and Workers
HOUSE BILL No. 2577 AN ACT enacting the addictions counselor licensure act; amending K.S.A. 74-7501 and K.S.A. 2009 Supp. 74-7507 and repealing the existing section; also repealing K.S.A. 65-6601, 65-6602,
House Study Bill 0 - Introduced HOUSE FILE BY (PROPOSED COMMITTEE ON HUMAN RESOURCES BILL BY CHAIRPERSON MILLER) A BILL FOR An Act relating to prescription authority for certain psychologists and making
Prescription Drug Monitoring Program Center of Excellence at Brandeis COE Briefing Mandating PDMP participation by medical providers: current status and experience in selected states Revision 1, February
No. 39. An act relating to patient choice and control at end of life. (S.77) It is hereby enacted by the General Assembly of the State of Vermont: Sec. 1. 18 V.S.A. chapter 113 is added to read: CHAPTER
New Jersey State Legislative Update Opioid Addiction and Abuse Prevention Legislative Package Moves Forward By Laurie A. Clark NJSIPP Legislative Counsel May 12, 2015 The New Jersey Legislature is currently
~tate of 'Urennessee PUBLIC CHAPTER NO. 430 SENATE BILL NO. 676 By Yager, Burks, Massey, McNally, Campfield, Gardenhire, Haile, Kelsey, Overbey, Tate Substituted for: House Bill No. 1264 By Dunn, Haynes,
00 -- H 11 SUBSTITUTE A AS AMENDED LC0/SUB A/ STATE OF RHODE ISLAND IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 00 A N A C T RELATING TO IDENTITY THEFT PROTECTION Introduced By: Representatives Gemma, Sullivan,
REFERENCE TITLE: accountancy board; certified public accountants State of Arizona House of Representatives Fifty-second Legislature First Regular Session HB Introduced by Representative Thorpe AN ACT AMENDING
Policy 6.007. ADMINISTRATION OF MEDICATIONS POLICY It is the policy of Cooperative Educational Services (C.E.S.) that students who require any medications to be administered during school hours, including
SENATE BILL 871 By Dickerson AN ACT to amend Tennessee Code Annotated, Title 33; Title 53; Title 56 and Title 63, relative to substance abuse. BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE:
Page 1 of 5 Title Northern Lakes CMH Policies Part 106 Supports and Services NLCMH Provided and Contract Subpart I Substance Abuse Services Policy No. 106.901 Subject Rights of Substance Abuse Applicability
Implementation of Florida s PDMP Rebecca R. Poston Program Manager December 1, 2012 Disclosure I have no vested interest in or affiliation with any corporate organizations offering financial support or
Session of SENATE BILL No. By Committee on Assessment and Taxation - 0 AN ACT concerning children and minors; enacting the Kansas foster parents' bill of rights act; relating to foster care; family foster
Janet Napolitano Governor Joey Ridenour Executive Director Arizona State Board of Nursing 4747 North 7th Street, Suite 200 Phoenix AZ 85014-3653 Phone (602) 889-5150 Fax (602) 889-5155 E-Mail: email@example.com
BUSINESS ASSOCIATE AGREEMENT THIS BUSINESS ASSOCIATE AGREEMENT is made and entered into as of the day of, 2013 ( Effective Date ), by and between [Physician Practice] on behalf of itself and each of its
GRANT REQUEST FOR PROPOSAL Issued By Minnesota Board of Pharmacy Project Title: Integration of Access to the MN Prescription Monitoring Program Database into the Clinical Workflow via the Electronic Medical
COLORADO REVISED STATUTES Title 12 Professions and Occupations Article 38.1 Nurse Aides Effective July 1, 2013 DISCLAIMER The Colorado Revised Statutes are available on the internet for public use by the
GEORGIA ~ STATUTE STATUTE DATE Enacted 1972 REGULATORY BODY PA DEFINED SCOPE OF PRACTICE PRESCRIBING/DISPENSING SUPERVISION DEFINED Georgia Code Annotated 16-13-21 (DEA registration); 43-34-100 et seq;
Senate Bill No. 38 Committee on Transportation and Homeland Security CHAPTER... AN ACT relating to criminal records; creating the Records and Technology Division of the Department of Public Safety; enumerating
Implementation of Florida s PDMP Rebecca Poston Program Manager Disclaimer I have no relevant financial relationships or commercial interest in the content presented in this program. Learning Objectives:
Prescription drug abuse trends Minnesota s Prescription Monitoring Program Carol Falkowski Drug Abuse Dialogues www.drugabusedialogues.com Barbara Carter, Manager MN Board of Pharmacy www.pmp.pharmacy.state.mn.us